Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Study Details
Study Description
Brief Summary
This protocol has a 2-part design:
This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and clinical activity of paxalisib in patients with newly-diagnosed glioblastoma (GBM) with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with temozolomide (TMZ).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Stage 1 Dose-Escalation and Maximum Tolerated Dose The dose-escalation portion of the study (Stage 1) will use a standard "3 + 3" design to determine the MTD for QD dosing.
Approximately 6 - 12 patients with newly diagnosed GBM will be enrolled in Stage 1.
The MTD for QD dosing will be determined. The initial dose level for QD dosing will be 60 mg (Dose Level 0). This dose is based on the phase 1 findings outlined in the rationale in the protocol, adding 1 dose level to test for a potential MTD increase.
Dose-escalation will occur in Stage 1:
-
The initial dose (Dose Level 0) for QD MTD determination in Step 1 will be 60 mg. Dose levels will increase in 15 mg steps;
-
The dose-escalation portion of the study (Stage 1) will use a standard "3 + 3" design to assess the safety, tolerability, and PK of paxalisib administered orally in 28-day cycles;
Decisions regarding dose-escalation and selection will be made by a Cohort Review Committee (CRC).
All AEs, including DLTs, will be reported, with severity assessed according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
After determination of the MTD, patients continue to receive their protocol-assigned dose levels of paxalisib until progression of their disease or an unacceptable toxicity, whichever occurs first.
Stage 2 Expansion stage (2) of the study will be a two-arm, randomized, open-label expansion study to further characterize the safety, tolerability and PK of paxalisib as well as to provide a preliminary assessment of single-agent activity of paxalisib in patients with GBM. Approximately 20 patients will be enrolled in the expansion cohort in 2 treatment arms (10 per am) to examine the PK of paxalisib in fed and fasted-conditions, according to the defined study eligibility criteria.
Stage 2 of the study will be initiated with recruitment of new patients as soon as the MTD has been determined.
Patients enrolled in Stage 2 may continue the study at the dose allocated until disease progression or unacceptable toxicity.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dose Escalation and Expansion Cohorts This is an open-label study. Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort. The initial cohort will receive an oral dose of 60 mg paxalisib QD (4 x 15 mg capsules). Patients of future dose cohorts will receive paxalisib at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where <1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD). In stage 1, dose escalation will occur for QD dosing. In stage 2, the expansion phase, patients will receive doses of oral paxalisib at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first. Patients will be randomized in a 1:1 ratio to fed or fasted schedules. |
Drug: Paxalisib (GDC-0084)
Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
|
Outcome Measures
Primary Outcome Measures
- Dose limiting toxicities (DLTs) [12 months]
The recommended Phase 2 dose and schedule. DLTs according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
Secondary Outcome Measures
- Incidence of treatment-emergent adverse events (TEAEs) [24 months]
TEAEs defined as any AE occurring or worsening on/after the first study drug dose and within 28 days after the last dose date. AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA).
- Incidence of serious adverse events (SAEs) [24 months]
AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA).
- Incidence of treatment-emergent Grade 3/4 clinical laboratory abnormalities. [24 months]
Clinical laboratory values will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, for applicable tests.
- Change in electrocardiogram (ECG) parameter QTc. [24 months]
The number and percentage of patients with an increase of QTc to a value ≥ 500 msec or a change from baseline of at least 60 msec will be presented overall and by visit.
- Change in left ventricular ejection fraction (LVEF). [24 months]
The number and percentage of patients with a drop in LVEF to a value of ≤ 45% from baseline will be presented overall and by visit.
- Progression-free survival interval using RANO Criteria. [24 months]
- Overall survival using RANO Criteria. [24 months]
Other Outcome Measures
- Pharmacokinetics of paxalisib as area under the curve from time 0 to last measurable time point (AUC0-last) and/or area under the curve from time 0 to infinity (AUC0-inf). [24 months]
- Pharmacokinetics of paxalisib as maximum (Cmax) and minimum concentration (Cmin). [24 months]
- Pharmacokinetics of paxalisib as time to reach Cmax (Tmax). [24 months]
- Pharmacokinetics of paxalisib as half-life. [24 months]
- Change in FDG-PET uptake in tumor and normal brain tissue in response to paxalisib in patients with measurable disease. [24 months]
- Disease control rate measured as the proportion of patients achieving a confirmed best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) according to RANO criteria. [24 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
Patients must meet all the following inclusion criteria to be eligible for enrollment into the study:
-
Age ≥ 18 years;
-
Life expectancy > 12 weeks;
-
Present with histologically confirmed intracranial (supratentorial) unmethylated MGMT promotor status GBM (WHO Grade lV astrocytoma) with a MGMT status that has been confirmed by validated PCR or validated alternate genomic analysis;
-
Have undergone maximal surgical resection of their tumor and within 6 weeks of surgery received initial treatment with XRT/TMZ which consisted of XRT by external beam to a partial brain field in daily fractions of 2.0 Gray (Gy), to a planned total dose to the tumor of 60.0 Gy, in conjunction with TMZ oral QD 75 mg/m2 in accordance with the Stupp regimen;
-
Must have measurable disease, according to RANO criteria for inclusion in the expansion cohort. Patients with non-measurable disease can be included in the dose-escalation cohorts;
-
KPS ≥ 70;
-
Cranial magnetic resonance imaging (MRI) must have been performed within 7 days prior to or on the day of the Randomization/Week 1 Visit;
-
Stable or decreasing corticosteroid dose within 7 days prior to the first dose;
-
Adequate bone marrow/hematological function within 7 days prior to Day 1;
-
Adequate liver and renal function within 14 days prior to Day 1;
-
International normalized ratio (INR) or prothrombin time (PT) (secs) and activated partial thromboplastin time (aPTT) within 7 days prior to randomization:
-
Patients must be willing to forego other drug therapy against the tumor while enrolled in the study.
Exclusion Criteria:
-
Previous radiotherapy to the brain or cytotoxic drug therapy (including Gliadel® wafers) in addition to the required postoperative radiation plus TMZ, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor prior to this regimen, will be excluded. Patients may have received or be receiving corticosteroids, analgesics, and other drugs to treat symptoms or prevent complications but the dose must be stable at treatment start. NOTE: 5 aminolevulinic acid-mediated photodynamic therapy administered prior to surgery to aid in optimal surgical resection is not considered a chemotherapy agent;
-
Any prior or anticipated concomitant treatment involving a medical device (such as Optune®) applying tumor treating fields (TTF);
-
QT interval time of ≥ 470 msec;
-
Undetermined/indeterminate MGMT status;
-
Diabetic patients; prediabetic patients treated with metformin;
-
Use of any CYP3A4 inducing or inhibiting agents;
-
Significant medical illnesses;
-
Women who are pregnant or who are lactating;
-
Diagnosed with infratentorial GBM, a tumor outside of brain or gliomatosis cerebri;
-
Evidence of recent hemorrhage on postoperative MRI of the brain;
-
Any previous malignancy; except for adequately controlled limited basal cell carcinoma of the skin, squamous carcinoma of the skin or carcinoma in situ of the cervix, or one which has been absent for ≥3 years;
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of California Los Angeles - Jonsson Comprehensive Cancer Center | Los Angeles | California | United States | 90095 |
| 2 | University of Colorado Cancer Center | Aurora | Colorado | United States | 80045 |
| 3 | Dana Farber Cancer Institute | Boston | Massachusetts | United States | 02115 |
| 4 | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | United States | 07601 |
| 5 | University of Oklahoma Health Sciences Center (Stephenson Cancer Center) | Oklahoma City | Oklahoma | United States | 73104 |
| 6 | MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- Kazia Therapeutics Limited
Investigators
- Study Director: James Garner, MD, Kazia Therapeutics Limited
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NVGN-0084-201